

# Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients

Flaminia Olearo,<sup>1,a,©</sup> Huyen Nguyen,<sup>2,3,a</sup> Fabrice Bonnet,<sup>4,5</sup> Sabine Yerly,<sup>6</sup> Gilles Wandeler,<sup>7</sup> Marcel Stoeckle,<sup>8</sup> Matthias Cavassini,<sup>9</sup> Alexandra Scherrer,<sup>2,3</sup> Dominique Costagliola,<sup>10</sup> Patrick Schmid,<sup>11</sup> Huldrych F Günthard,<sup>2,3</sup> Enos Bernasconi,<sup>12</sup> Jürg Boeni,<sup>3</sup> Antonella D'Arminio Monforte,<sup>13</sup> Maurizio Zazzi,<sup>14</sup> Barbara Rossetti,<sup>15</sup> Didier Neau,<sup>5</sup> Pantxika Bellecave,<sup>16</sup> Bart Rijnders,<sup>17</sup> Peter Reiss,<sup>17</sup> Ferdinand Wit,<sup>17</sup> Roger Kouyos,<sup>2,3,b</sup> and Alexandra Calmy<sup>1,b</sup>

<sup>1</sup>Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Switzerland; <sup>2</sup>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland; <sup>3</sup>Institute of Medical Virology, Swiss National Reference Centre for Retroviruses, University of Zurich, Switzerland; <sup>4</sup>University of Bordeaux, Institut de Santé Publique d'Épidémiologie et de Développement (ISPED), U1219 INSERM, France; <sup>5</sup>Centre Hospitalier Universitaire de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, France; <sup>6</sup>Laboratory of Virology, Geneva University Hospitals and Faculty of Medicine, Switzerland; <sup>7</sup>Institute of Social and Preventive Medicine, University Hospital of Bern, Switzerland; <sup>8</sup>Division of Infectious Diseases, University Hospital of Basel, Switzerland; <sup>9</sup>Division of Infectious Diseases, Lausanne University Hospital, Switzerland; <sup>10</sup>INSERM, Sorbonne Université, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France; <sup>11</sup>Division of Infectious Diseases and Hospital Epidemiology, St. Gallen Cantonal Hospital, Switzerland; <sup>12</sup>Division of Infectious Diseases, Ospedale Regionale di Lugano, Switzerland; <sup>13</sup>Department of Health Sciences, Institute of Infectious and Tropical Medicine, L'Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo, University of Milan, Italy; <sup>14</sup>Department of Medical Biotechnology, University of Siena, Italy; <sup>15</sup>Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy; <sup>16</sup>Virology Laboratory, Centre Hospitalier Universitaire de Bordeaux, France; <sup>17</sup>Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands

In “Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients” *Open Forum Infectious Diseases*, Volume 6, Issue 10,

October 2019, ofz330, <https://doi.org/10.1093/ofid/ofz330>, the surname of a co-author, Dominique Costagliola, was misspelled. This was corrected in the new version of the manuscript.

## Open Forum Infectious Diseases®

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)  
 DOI: 10.1093/ofid/ofz500